NCT04515979 2024-12-09
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
MedPacto, Inc.
Phase 2 Terminated
MedPacto, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Eli Lilly and Company
Arog Pharmaceuticals, Inc.
Bayer